First Time Loading...

Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 775 000 KRW 0.65% Market Closed
Updated: Apr 29, 2024

Samsung Biologics Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Samsung Biologics Co Ltd
Operating Income Peer Comparison

Comparables:
P
087010
K
278650
S
237690
F
220100
L
141080

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Samsung Biologics Co Ltd
KRX:207940
Operating Income
₩1.1T
CAGR 3-Years
56%
CAGR 5-Years
82%
CAGR 10-Years
N/A
P
Peptron Inc
KOSDAQ:087010
Operating Income
-₩15.9B
CAGR 3-Years
3%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Operating Income
-₩1.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Operating Income
₩33.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Operating Income
-₩8.4B
CAGR 3-Years
-20%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Operating Income
-₩80.8B
CAGR 3-Years
-40%
CAGR 5-Years
-38%
CAGR 10-Years
-29%

See Also

What is Samsung Biologics Co Ltd's Operating Income?
Operating Income
1.1T KRW

Based on the financial report for Dec 31, 2023, Samsung Biologics Co Ltd's Operating Income amounts to 1.1T KRW.

What is Samsung Biologics Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
82%

Over the last year, the Operating Income growth was 13%. The average annual Operating Income growth rates for Samsung Biologics Co Ltd have been 56% over the past three years , 82% over the past five years .